Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
Chow, Laura Q M
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. [electronic resource] - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Video-Audio Media
1548-8756
10.14694/EdBook_AM.2013.33.e280 doi
Animals
Antibodies--adverse effects
Antineoplastic Agents--adverse effects
Apoptosis--drug effects
B7-H1 Antigen--antagonists & inhibitors
CTLA-4 Antigen--antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung--drug therapy
Humans
Immunotherapy--adverse effects
Lung Neoplasms--drug therapy
Lymphocyte Activation--drug effects
Molecular Targeted Therapy--adverse effects
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Risk Factors
Signal Transduction--drug effects
Treatment Outcome
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. [electronic resource] - American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2013
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Video-Audio Media
1548-8756
10.14694/EdBook_AM.2013.33.e280 doi
Animals
Antibodies--adverse effects
Antineoplastic Agents--adverse effects
Apoptosis--drug effects
B7-H1 Antigen--antagonists & inhibitors
CTLA-4 Antigen--antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung--drug therapy
Humans
Immunotherapy--adverse effects
Lung Neoplasms--drug therapy
Lymphocyte Activation--drug effects
Molecular Targeted Therapy--adverse effects
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Risk Factors
Signal Transduction--drug effects
Treatment Outcome